Determinants of bronchodilator responsiveness in patients with controlled asthma

Journal of Asthma

Volumn 43, Issue 1, 2006, Pages 71-74

  Koga, Takeharu ^a   Kamimura, Tomoko ^a   Oshita, Yuichi ^a   Narita, Yuko ^a   Mukaino, Tatsuya ^a   Nishimura, Munetsugu ^a   Mizoguchi, Yusuke ^a   Aizawa, Hisamichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Asthma; Bronchodilator; Lung function; Reversibility; Severity

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; SALBUTAMOL;

ADULT; AGING; AIRFLOW; ARTICLE; BRONCHODILATATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MILD INTERMITTENT ASTHMA; MODERATE PERSISTENT ASTHMA; PREDICTION; SEVERE PERSISTENT ASTHMA; SHORT COURSE THERAPY; SPIROMETRY; THERAPY EFFECT;

ADULT; AGE FACTORS; AGED; ALBUTEROL; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY VENTILATION; SPIROMETRY;

EID: 33745253408     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900500448662     Document Type: Article

References (28)

1. Global initiative for asthma. Global strategy for asthma management and prevention: National Institutes of Health, 2002:Publication 02-3659.
2. British Guideline on the Management of Asthma. Thorax 2003; 58:il-94.
3. Burchard EG, Avila PC, Nazario S, et al. Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma. Am J Respir Crit Care Med 2004; 169:386-392.
4. Boulet LP, Turcotte H, Turcot O, et al. Airway inflammation in asthma with incomplete reversibility of airflow obstruction. Respir Med 2003; 97:739-744.
5. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109:410-418.
6. Faul JL, Demers EA, Burke CM, et al. Alterations in airway inflammation and lung function during corticosteroid therapy for atopic asthma. Chest 2002; 121:1414-1420.
7. Vonk JM, Jongepier H, Panhuysen CI, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003; 58:322-327.
8. ten BA, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744-748.
9. Holt S, Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: Meta-analysis. BMJ 2001; 323:253-256.
10. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6(suppl 16):5-40.
11. Chhabra SK, Vijayan VK, Gupta R, De S. Expression of bronchodilator response: Comparison of four indices. Respir Med 2002; 96:611-614.
12. Quadrelli SA, Roncoroni AJ, Montiel GC. Evaluation of bronchodilator response in patients with airway obstruction. Respir Med 1999; 93:630-636.
13. Weir DC, Sherwood Burge P. Measures of reversibility in response to bronchodilators in chronic airflow obstruction: Relation to airway calibre. Thorax 1991; 46:43-45.
14. Brand PL, Quanjer PH, Postma DS, et al. Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax 1992; 47:429-436.
15. Bellia V, Cibella F, Cuttitta G, et al. Effect of age upon airway obstruction and reversibility in adult patients with asthma. Chest 1998; 114:1336-1342.
16. Sippel JM, Holden WE, Tilles SA, et al. Exhaled nitric oxide levels correlate with measures of disease control in asthma. J Allergy Clin Immunol 2000; 106:645-650.
17. Jones SL, Kittelson J, Cowan JO, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001; 164:738-743.
18. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 1994; 97:29-37.
19. Kerstjens HA, Brand PL, Quanjer PH, et al. Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group. Thorax 1993; 48:722-729.
20. 1/vital capacity ratio: A longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med 2002; 165:1480-1488.
21. Little SA, Sproule MW, Cowan MD, et al. High resolution computed tomographic assessment of airway wall thickness in chronic asthma: Reproducibility and relationship with lung function and severity. Thorax 2002; 573:247-253.
22. Benayoun L, Druilhe A, Dombret MC, et al. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003; 167:1360-1368.
23. Cassino C, Berger KI, Goldring RM, et al. Duration of asthma and physiologic outcomes in elderly nonsmokers. Am J Respir Crit Care Med 2000; 162:1423-1428.
24. Rodrigo G, Rodrigo C. Effect of age on bronchodilator response in acute severe asthma treatment. Chest 1997; 112:19-23.
25. Kizkin O, Turker G, Hacievliyagil SS, et al. Asthma, age, and early reversibility testing. J Asthma 2003; 40:317-321.
26. Duncan PG, Brink C, Douglas JS. Beta-receptors during aging in respiratory tissues. Eur J Pharmacol 1982; 78:45-52.
27. Janssens JP, Pache JC, Nicod LP. Physiological changes in respiratory function associated with ageing. Eur Respir J 1999; 13:197-205.
28. Little SA, MacLeod KJ, Chalmers GW, et al. Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma. Am J Med 2002; 112:446-452.